First-in-Class Drug Against CD79b Improves Survival in DLBCL First-in-Class Drug Against CD79b Improves Survival in DLBCL

The first-in-class antibody-drug conjugate polatuzumab vedotin significantly improved response and overall survival in relapsed or refractory diffuse large B-cell lymphoma.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news